Meeting
2019 ASCO Annual Meeting
Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
Authors
Joel W. Neal
Stanford University and Stanford Cancer Institute, Stanford, CA
Joel W. Neal , Daniel Hausrath , Heather A. Wakelee , Kristen Cunanan , Stephen V. Liu , Mandeep Banwait , Lecia V. Sequist , Kevin Stirling , Zofia Piotrowska
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9083)
DOI
10.1200/JCO.2019.37.15_suppl.9083
Abstract #
9083
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).
First Author: Yuki Sato
Poster
2022 ASCO Annual Meeting
Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
First Author: Yi-Long Wu
Poster
2019 ASCO Annual Meeting
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn